GTS Securities’s Apellis Pharmaceuticals APLS Stock Holding History

GTS Securities’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,604	Closed	-$628K	–	1356
2026 Q1	$628K	Buy	+15,604	New	+$336K	0.02%	616
2024 Q4	–	Sell	-11,362	Closed	-$328K	–	1403
2024 Q3	$328K	Buy	11,362 +3,205	+39%	+$119K	﹤0.01%	3220
2024 Q2	$313K	Buy	8,157 +2,660	+48%	+$120K	﹤0.01%	3086
2024 Q1	$323K	Sell	5,497 -46,550	-89%	-$2.97M	﹤0.01%	2933
2023 Q4	$3.12M	Buy	52,047 +15,253	+41%	+$774K	0.01%	1325
2023 Q3	$1.4M	Buy	36,794 +22,465	+157%	+$987K	﹤0.01%	1766
2023 Q2	$1.31M	Buy	+14,329	New	+$1.24M	0.04%	361

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GTS Securities's APLS Position: Q2 2026 in Review

GTS Securities sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 15,604 shares — an estimated $628K sold.

GTS Securities first reported a position in APLS in Q2 2023 and held it in 7 quarters. The position peaked at $3.12M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

GTS Securities reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 15,604 Apellis Pharmaceuticals shares in Q2 2026, an estimated $628K.
GTS Securities first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 7 quarters.
GTS Securities's Apellis Pharmaceuticals position peaked at $3.12M in Q4 2023.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.